You are here: Industry Insights > Forxiga

News List

Dapnat launch to boost Natco’s presence in India’s diabetes market but concerted efforts required, s expresspharma
April 29, 2020
Natco is a new player within the cardiovascular and diabetes therapeutic space, launching its Cardiology and Diabetic (CnD) division in early 2017.
Forxiga successful in DAPA-HF heart failure trial pharmatimes
March 31, 2020
New data from a sub-analysis of AstraZeneca’s Phase III DAPA-HF trial has shown that Forxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo.
CHMP recommends AstraZeneca’s Qtrilmet for type 2 diabetes pharmaceutical-technology
September 25, 2019
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the marketing authorisation of AstraZeneca’s Qtrilmet to treat type 2 diabetes in adults.
Forxiga approved in Japan for type-1 diabetes worldpharmanews
March 28, 2019
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D).
EU approves AZ' Forxiga for type I diabetes pharmatimes
March 27, 2019
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC) for type I diabetes.

Previous page 1 2 Next page